Experimental stem cells offered to kids with rare COVID complication
NCT ID NCT04456439
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study provides early access to an experimental stem cell treatment called remestemcel-L for children aged 2 months to 17 years with MIS-C, a severe inflammatory condition linked to COVID-19. The treatment aims to calm the immune system and reduce inflammation. Participants receive up to two infusions of the cells, along with standard medicines to prevent allergic reactions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- remestemcel-L (human mesenchymal stromal cells)
- What this could lead to
- If successful, this could provide a treatment option for children with severe MIS-C, a rare but serious inflammatory condition linked to COVID-19.
- What could go wrong
- This is an expanded access program, not a full clinical trial, so results are limited. The number of participants is small, and the therapy may not work for all children or could cause side effects like allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C) ASSOCIATED WITH CORONAVIRUS DISEASE (COVID-19) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.